Show simple item record

dc.contributor.authorHippe, E
dc.contributor.authorWestin, Jan
dc.contributor.authorWisloff, F
dc.date.accessioned2019-10-25T00:50:35Z
dc.date.available2019-10-25T00:50:35Z
dc.date.created2017-03-28 23:08
dc.date.issued2005
dc.identifieroai:lup.lub.lu.se:9cffe7fd-6da1-4d4c-9491-d18dd3261f39
dc.identifierhttp://lup.lub.lu.se/record/253758
dc.identifierhttp://dx.doi.org/10.1111/j.1600-0609.2004.00379.x
dc.identifierpmid:15693787
dc.identifierwos:000226773800001
dc.identifierscopus:14044279843
dc.identifier.urihttp://hdl.handle.net/20.500.12424/1180456
dc.description.abstractThe accomplishments of the Nordic Myeloma Study Group (NMSG) during its first 15 yr are briefly surveyed, together with a discussion of principles guiding the group's clinical trials and of problems that need to be addressed in coming years. The group has so far carried out 12 clinical trials, comprising more than 2500 patients, spanning from minor phase II to large randomised phase III trials. At the time of writing, two randomised trials are running (comparing two doses of i.v. pamidronate, and melphalan-prednisone (MP) vs. MP-thalidomide to elderly patients). The group has strived for a simple organisation with much responsibility delegated to regional coordinators (Denmark 3, Norway 5, Sweden 5). With regard to trial design, the group has considered it important that studies are based on sound scientific questions, are simple to handle for the participants, population based, investigator initiated, include quality of life and health resources assessment as end-points, and can be used as basis for diverse scientific spin-off projects. Like other clinical trial groups, NMSG faces a number of challenges in coming years. The financial situation for independent investigator-initiated trials is far from satisfactory, especially with regard to the resource-consuming implementation of more stringent good clinical practice rules and ethical committee demands. NMSG has also encountered increasing difficulties in recruiting patients to recent trials, partly because of problems related to participating physicians (lack of support, laborious paper work, insufficient credit for participation). Solutions to these problems have to be found if industry-independent clinical trial groups are to survive.
dc.language.isoeng
dc.publisherWiley-Blackwell
dc.sourceEuropean Journal of Haematology; 74(3), pp 185-193 (2005)
dc.subjectHematologi
dc.subjectcooperative groups
dc.subjectcare programme
dc.subjecthealth
dc.subjectquality of life
dc.subjectchemotherapy
dc.subjectmultiple myeloma
dc.subjectclinical trial
dc.subjecthistorical article
dc.titleNordic Myeloma Study Group, the first 15 years: Scientific collaboration and improvement of patient care
dc.typecontributiontojournal/systematicreview
ge.collectioncodeOAIDATA
ge.dataimportlabelOAI metadata object
ge.identifier.legacyglobethics:10864052
ge.identifier.permalinkhttps://www.globethics.net/gel/10864052
ge.lastmodificationdate2017-03-28 23:08
ge.lastmodificationuseradmin@pointsoftware.ch (import)
ge.submissions0
ge.oai.exportid148650
ge.oai.repositoryid882
ge.oai.setnamePublications intended for Swepub
ge.oai.setnameAll LU publications
ge.oai.setspeccontributiontojournal:systematicreview
ge.oai.setspecLU_SWEPUB
ge.oai.streamid2
ge.setnameGlobeEthicsLib
ge.setspecglobeethicslib
ge.linkhttp://lup.lub.lu.se/record/253758
ge.linkhttps://dx.doi.org/10.1111/j.1600-0609.2004.00379.x


This item appears in the following Collection(s)

Show simple item record